MIFH
BDTX icon

Migdal Insurance & Financial Holdings’s Black Diamond Therapeutics BDTX Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-20,770
Closed -$504K – 590
2021
Q1 		$504K Buy
20,770
+12,889
+164% +$348K 0.01% 318
2020
Q4 		$253K Buy
+7,881
New +$259K ﹤0.01% 288

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Migdal Insurance & Financial Holdings's BDTX Position: Q2 2021 in Review

Migdal Insurance & Financial Holdings sold out of Black Diamond Therapeutics (BDTX) in Q2 2021, closing a stake of 20,770 shares — an estimated $504K sold.

Migdal Insurance & Financial Holdings first reported a position in BDTX in Q4 2020 and held it in 2 quarters. The position peaked at $504K in Q1 2021. 102 funds tracked by Wall St. Rank hold BDTX as of Q2 2021.

  • Migdal Insurance & Financial Holdings reported no remaining Black Diamond Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 20,770 Black Diamond Therapeutics shares in Q2 2021, an estimated $504K.
  • Migdal Insurance & Financial Holdings first reported a position in Black Diamond Therapeutics in Q4 2020 and held it in 2 quarters.
  • Migdal Insurance & Financial Holdings's Black Diamond Therapeutics position peaked at $504K in Q1 2021.
  • 102 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2021.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q2 2021, filed 4 Aug 2021.